Keyphrases
Novel Therapies
100%
Hodgkin Lymphoma
100%
Brentuximab Vedotin
100%
PD-1 Inhibitor
75%
First-line Therapy
50%
Second-line Therapy
50%
Clinical Trials
25%
Overall Response Rate
25%
Infusion Reaction
25%
Pretransplant
25%
Older Patients
25%
Newly Diagnosed
25%
Improved Outcomes
25%
Complete Response Rate
25%
New Drugs
25%
Conventional Chemotherapy
25%
Prior Chemotherapy
25%
Programmed Death-ligand 1 (PD-L1)
25%
New Agents
25%
Bleomycin
25%
Post-transplant Outcomes
25%
Nivolumab
25%
Advanced Stage Disease
25%
Previously Untreated
25%
Relapse Risk
25%
Vinblastine
25%
Combination Regimen
25%
Pulmonary Toxicity
25%
High Response Rate
25%
Dacarbazine
25%
Adriamycin
25%
Immune Toxicity
25%
Pembrolizumab
25%
Adequate Therapy
25%
Theoretical Potential
25%
Pharmacology, Toxicology and Pharmaceutical Science
Hodgkin Disease
100%
Brentuximab Vedotin
100%
Clinical Trial
25%
Chemotherapy
25%
Patient History of Chemotherapy
25%
Doxorubicin
25%
Bleomycin
25%
Nivolumab
25%
Vinblastine
25%
Lung Toxicity
25%
Dacarbazine
25%
Infusion Related Reaction
25%
Programmed Death 1 Receptor
25%
Pembrolizumab
25%
Diseases
25%
Medicine and Dentistry
Hodgkin's Lymphoma
100%
Brentuximab Vedotin
100%
Clinical Trial
25%
Patient History of Chemotherapy
25%
Programmed Death 1 Receptor
25%
Doxorubicin
25%
Bleomycin
25%
Immunity
25%
Nivolumab
25%
Vinblastine
25%
Pulmonary Toxicity
25%
Dacarbazine
25%
Infusion Related Reaction
25%
Pembrolizumab
25%
Diseases
25%